Ann: SECuRE trial update, page-20

Please read the announcement - the news is outstanding and easy to read, hence the rising shareprice.

a) 12 out of 13 pre-chemo patients experiencing a greater than 35% reduction.

b) Almost half of the 13 experiencing drops of 80% or greater.

c) One participant has had 4 additional doses and achieved disease control over 2 years since first treatment.

d) When doses are increased to 8 GBq (for 3 pre-chemo patients), then things get really interesting:

e) All three received greater than 80% in PSA reductions.

f) Two of the three showed above 95% in PSA reductions

g) One showed a COMPLETE RESPONSE to date.

As doses go up - within an effective safety profile - so to does reduction in PSA, with one showing a complete response to date.

No wonder the CEO describe the results as extraordinary.

Above is not financial advice and my opinion only.